See more : MRS Logística S.A. (MRSA6B.SA) Income Statement Analysis – Financial Results
Complete financial analysis of Cellectar Biosciences, Inc. (CLRB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cellectar Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Rockhaven Resources Ltd. (RK.V) Income Statement Analysis – Financial Results
- Foremost Lithium Resource & Technology Ltd. (FAT.CN) Income Statement Analysis – Financial Results
- Samsung Electro-Mechanics Co., Ltd. (009150.KS) Income Statement Analysis – Financial Results
- Rabbit Holdings Public Company Limited (RABBIT.BK) Income Statement Analysis – Financial Results
- GeoPark Limited (0MDP.L) Income Statement Analysis – Financial Results
Cellectar Biosciences, Inc. (CLRB)
About Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -11.00K | 33.33K | 96.31K | 125.97K | 0.00 | 0.00 | 12.58K | 4.96K |
| Cost of Revenue | 192.38K | 238.87K | 227.64K | 207.93K | 189.36K | 82.27K | 1.55M | 356.67K | 362.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.54K |
| Gross Profit | -192.38K | -238.87K | -227.64K | -207.93K | -189.36K | -82.27K | -1.55M | -356.67K | -362.50K | 0.00 | 0.00 | 0.00 | -11.00K | 33.33K | 96.31K | 125.97K | 0.00 | 0.00 | 12.58K | 2.42K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 48.85% |
| Research & Development | 27.27M | 19.22M | 17.59M | 10.14M | 9.00M | 6.84M | 9.47M | 4.75M | 5.16M | 5.96M | 6.86M | 5.12M | 3.60M | 3.00M | 8.08M | 14.53M | 17.43M | 6.44M | 1.14M | 261.77K |
| General & Administrative | 10.75M | 9.59M | 6.54M | 5.15M | 5.18M | 4.82M | 4.14M | 4.70M | 3.40M | 3.70M | 4.44M | 3.63M | 0.00 | 2.49M | 2.18M | 2.19M | 2.87M | 2.49M | 0.00 | 0.00 |
| Selling & Marketing | 945.18K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.69M | 9.59M | 6.54M | 5.15M | 5.18M | 4.82M | 4.14M | 4.70M | 3.40M | 3.70M | 4.44M | 3.63M | 2.69M | 2.49M | 2.18M | 2.19M | 2.87M | 2.49M | 1.44M | 365.88K |
| Other Expenses | 0.00 | 0.00 | 6.63K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 38.96M | 28.81M | 24.13M | 15.29M | 14.18M | 11.66M | 13.60M | 9.45M | 8.55M | 9.67M | 11.30M | 8.75M | 6.29M | 5.48M | 10.26M | 16.72M | 20.29M | 8.93M | 2.58M | 627.64K |
| Cost & Expenses | 38.96M | 28.81M | 24.13M | 15.29M | 14.18M | 11.66M | 13.60M | 9.45M | 8.55M | 9.67M | 11.30M | 8.75M | 6.29M | 5.48M | 10.26M | 16.72M | 20.29M | 8.93M | 2.58M | 630.18K |
| Interest Income | 0.00 | 152.52K | 2.28K | 10.90K | 42.71K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00K | 4.50K | 2.42K | 1.01K | 130.61K | 729.92K | 637.75K | 49.88K | 95.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.69K | 16.61K | 7.90K | 841.00 | 446.31K | 9.35K | 9.34K | 430.02K | 2.42K | 1.01K | 130.61K | 0.00 | 0.00 | 0.00 | 208.74K |
| Depreciation & Amortization | 192.38K | 238.87K | 227.64K | 207.93K | 189.36K | 82.27K | 1.55M | 356.67K | 362.50K | 367.20K | 424.76K | 497.25K | 584.84K | 35.34K | 32.35K | 16.89K | 15.37K | 9.52K | 3.24K | 2.54K |
| EBITDA | -38.77M | -28.67M | -23.98M | -15.15M | -13.90M | -13.16M | -12.05M | -9.09M | -8.19M | -9.30M | -10.88M | -8.29M | -6.33M | -12.96M | -10.17M | -16.59M | -19.54M | -8.28M | -2.94M | -604.01K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 45,388.96% | -38,876.20% | 2,049.87% | -13,164.56% | 0.00% | 0.00% | -16,968.75% | -12,172.63% |
| Operating Income | -38.96M | -28.81M | -24.13M | -15.29M | -14.18M | -13.33M | -13.60M | -9.45M | -8.76M | -9.89M | -12.40M | -8.75M | -7.04M | -5.45M | -10.17M | -16.59M | -20.29M | -8.93M | -5.09M | -625.22K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 63,979.27% | -16,351.72% | -10,555.25% | -13,170.82% | 0.00% | 0.00% | -40,428.32% | -12,600.14% |
| Total Other Income/Expenses | 917.15K | 152.52K | 8.92K | 196.18K | 85.71K | 91.74K | 38.68K | 3.27M | 3.26M | 1.78M | 522.76K | -42.19K | -1.89M | -7.20M | -12.11M | 139.61K | 737.05K | 382.63K | -487.02K | -190.07K |
| Income Before Tax | -38.04M | -28.66M | -24.12M | -15.09M | -14.09M | -13.24M | -13.56M | -6.18M | -5.50M | -8.11M | -10.78M | -8.80M | -7.75M | -12.65M | -26.28M | -22.96M | -29.72M | -8.55M | -3.16M | -815.29K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 70,469.15% | -37,960.15% | -27,289.52% | -18,227.50% | 0.00% | 0.00% | -25,146.86% | -16,430.57% |
| Income Tax Expense | -60.00K | -60.00K | -152.20K | -337.63K | -218.51K | -1.55M | -38.68K | -3.27M | -3.42M | -1.56M | -522.76K | 9.34K | 1.14M | -7.55M | 12.11M | -139.61K | -737.05K | -643.75K | 487.02K | 0.00 |
| Net Income | -37.98M | -28.60M | -23.97M | -14.76M | -13.87M | -13.24M | -13.56M | -6.18M | -5.50M | -8.11M | -10.78M | -8.80M | -7.44M | 2.10M | -22.27M | -16.45M | -19.56M | -8.29M | -3.05M | -815.29K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 67,594.75% | 6,286.05% | -23,125.72% | -13,059.99% | 0.00% | 0.00% | -24,264.14% | -16,430.57% |
| EPS | -3.11 | -4.05 | -4.32 | -7.45 | -18.08 | -44.70 | -96.66 | -141.54 | -702.78 | -1.77K | -3.86K | -4.28K | -6.21K | -31.02K | -1.01M | -1.18M | -1.63M | -690.50K | -254.45K | -180.51K |
| EPS Diluted | -3.11 | -4.05 | -4.32 | -7.45 | -18.08 | -44.70 | -96.66 | -141.54 | -702.78 | -1.77K | -3.86K | -4.28K | -6.21K | -31.02K | -1.01M | -1.18M | -1.63M | -690.50K | -254.45K | -180.51K |
| Weighted Avg Shares Out | 12.22M | 7.06M | 5.55M | 1.98M | 767.51K | 296.20K | 140.31K | 43.67K | 7.82K | 4.59K | 2.79K | 2.06K | 1.20K | 147.00 | 22.00 | 14.00 | 12.00 | 12.00 | 12.00 | 4.52 |
| Weighted Avg Shares Out (Dil) | 12.22M | 7.06M | 5.55M | 1.98M | 767.51K | 296.20K | 140.31K | 43.67K | 7.82K | 4.59K | 2.79K | 2.06K | 1.20K | 147.00 | 22.00 | 14.00 | 12.00 | 12.00 | 12.00 | 4.52 |
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day
FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating...
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024
FLORHAM PARK, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will report...
Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript
Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year...
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will report...
Cellectar Biosciences to Present at the 36th Annual Roth Conference
FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that Jim Caruso, president and...
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
FLORHAM PARK, N.J., March 04, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that iopofosine I 131 in...
Cellectar Biosciences: A Shoestring Opportunity You're About To Miss
Cellectar Biosciences is a developmental biotech focused on a radiolabeled phospholipid for hematologic malignancies, with a focus on Waldenstrom's macroglobulinemia. Their most advanced development is in Waldenstrom's, with positive trial results and plans to file for Accelerated Approval. The company...
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
FLORHAM PARK, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that James Caruso, president and...
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study
Study of Iopofosine I 131 Supported by $2 Million Grant from the National Institute of Health's National Cancer Institute (NCI) Study of Iopofosine I 131 Supported by $2 Million Grant from the National Institute of Health's National Cancer Institute (NCI)
Source: https://incomestatements.info
Category: Stock Reports